A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)
1 other identifier
observational
300
1 country
1
Brief Summary
There are many controversies and limitations in the management of Upper Tract Urothelial cancer. A prospective registry is set up for patients in our hospital, aim to have a comprehensive prospective assessment of the physical and biological effects of Upper Tract Urothelial cancer in our patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2021
CompletedFirst Submitted
Initial submission to the registry
June 24, 2022
CompletedFirst Posted
Study publicly available on registry
June 30, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2030
January 23, 2024
January 1, 2024
9.2 years
June 24, 2022
January 21, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Long-term survival
Long-term survival
10 years
Secondary Outcomes (3)
Recurrence rate of UTUC
10 years
Progression rate of UTUC
10 years
Complications
10 years
Eligibility Criteria
A total of 300 Chinese patients with various stage of UTUC will be recruited for the study.
You may qualify if:
- Male patients \> 18 years old
- Patients who has presence of UTUC and pending for surgery
- Patients who has history of UTUC with any intervention performed
You may not qualify if:
- \- Patients fail to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Prince of Wales Hospital
Hong Kong, Hong Kong
Related Publications (5)
Cauberg EC, Salomons MA, Kummerlin IP, de Reijke TM, Zwinderman AH, de la Rosette JJ, Kate FJ, Laguna Pes MP. Trends in epidemiology and treatment of upper urinary tract tumours in the Netherlands 1995-2005: an analysis of PALGA, the Dutch national histopathology registry. BJU Int. 2010 Apr;105(7):922-7. doi: 10.1111/j.1464-410X.2009.08889.x. Epub 2009 Oct 5.
PMID: 19804428BACKGROUNDLughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012 Jul;62(1):100-14. doi: 10.1016/j.eururo.2012.02.030. Epub 2012 Feb 23.
PMID: 22381168BACKGROUNDMellemgaard A, Carstensen B, Norgaard N, Knudsen JB, Olsen JH. Trends in the incidence of cancer of the kidney, pelvis, ureter and bladder in Denmark 1943-88. Scand J Urol Nephrol. 1993;27(3):327-32. doi: 10.3109/00365599309180442.
PMID: 8290911BACKGROUNDMunoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000 Nov;164(5):1523-5.
PMID: 11025695BACKGROUNDRemzi M, Shariat S, Huebner W, Fajkovic H, Seitz C. Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol. 2011 Apr;3(2):69-80. doi: 10.1177/1756287211403349.
PMID: 21869907BACKGROUND
Study Officials
- PRINCIPAL INVESTIGATOR
Jeremy Yuen-Chun TEOH, FRCS(Ed) MBBS
Chinese University of Hong Kong
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
June 24, 2022
First Posted
June 30, 2022
Study Start
November 1, 2021
Primary Completion (Estimated)
December 30, 2030
Study Completion (Estimated)
December 30, 2030
Last Updated
January 23, 2024
Record last verified: 2024-01